Abstract | OBJECTIVES: METHODS: RESULTS:
Methylselenocysteine (MSC) significantly inhibited LNCaP tumor growth (P < 0.05). AR expression in tumor tissues and serum PSA levels were considerably decreased in MSC-treated mice compared to the vehicle controls. CONCLUSIONS: Pharmacological dose of MSC inhibits the growth of LNCaP human prostate cancer in vivo accompanied by a decrease in the expression of AR and PSA. These findings suggest that selenium (MSC) can serve as a therapeutic agent aimed at disruption of AR signaling for prostate cancer.
|
Authors | Soo Ok Lee, Jae Yeon Chun, Nagalakshmi Nadiminty, Donald L Trump, Clement Ip, Yan Dong, Allen C Gao |
Journal | The Prostate
(Prostate)
Vol. 66
Issue 10
Pg. 1070-5
(Jul 01 2006)
ISSN: 0270-4137 [Print] United States |
PMID | 16637076
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | Copyright 2005 Wiley-Liss, Inc. |
Chemical References |
- Anticarcinogenic Agents
- Organoselenium Compounds
- Receptors, Androgen
- Selenocysteine
- Prostate-Specific Antigen
- Selenium
- Cysteine
- selenomethylselenocysteine
|
Topics |
- Animals
- Anticarcinogenic Agents
(pharmacology)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Cysteine
(analogs & derivatives, pharmacology)
- Gene Expression Regulation, Neoplastic
(drug effects)
- Humans
- Male
- Mice
- Mice, Nude
- Organoselenium Compounds
(pharmacology)
- Prostate-Specific Antigen
(analysis, genetics, physiology)
- Prostatic Neoplasms
(drug therapy, genetics, pathology, physiopathology)
- Receptors, Androgen
(analysis, genetics)
- Selenium
(pharmacology, therapeutic use)
- Selenocysteine
(analogs & derivatives)
- Xenograft Model Antitumor Assays
|